Eli Lilly reports broad benefits for experimental obesity drug retatrutide (LLY:NYSE)
· seekingalpha.com
Eli Lilly’s retatrutide shows up to 28% weight loss plus better diabetes, sleep apnea and arthritis in Phase 3 trials—see what it means for LLY investors.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...